Patients with systemic lupus erythematosus and hydroxychloroquine-related retinal toxicity had a greater prevalence of antiretinal autoantibodies. Patients with systemic lupus erythematosus (SLE) and ...

Scientists at the Garvan Institute of Medical Research have discovered how a viral infection causes autoimmune disease, ...

Discover a non-invasive diagnostic model for primary Sjögren’s disease using salivary biomarkers, serum autoantibodies, and ...

Cellular damage occurs when sensitized T-lymphocytes and/or autoantibodies bind to thyroid cell membranes causing cell lysis and inflammatory reactions. Alterations in thyroid gland function ...

Inc. (Nasdaq: VERA) today announced that on January 8, 2025, the Compensation Committee granted inducement awards consisting ...

Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on Vera Therapeutics (VERA – Research Report). The associated price ...

Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative ...

The clinical use of TRAb measurements for the diagnosis and follow-up of AITD remains a matter of controversy and differs geographically. The differential diagnosis of hyperthyroidism can be ...

Biomarkers found in the blood can reveal changes in the body that may signal lung cancer before symptoms appear.

The Phase 1 GALLOP study evaluating the investigational CAR-T therapy, CB-010, for treatment of lupus nephritis has launched.

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vera Therapeutics (VERA – Research Report) today and set a price target of $75.00.